HUNTLEY, Ill., June 23, 2026 -(BUSINESS WIRE)- Life Spine, Inc., a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spinal disorders, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the VersaLift™ Expandable Interbody System, a Micro Invasive™ solution for TLIF and PLIF procedures featuring a low 6mm starting height.
Life Spine Receives FDA 510(k) Clearance for VersaLift™ Expandable Interbody System Featuring a 6mm Starting Height
1 min read Premium comments
TLIFLife SpineFDA 510(k) clearanceVersaLift Expandable Interbody SystemPLIF6mm starting height
Designed to support minimally invasive surgical access, VersaLift offers one of the smallest starting heights available for a TLIF expandable interbody implant, beginning at just 6mm. Approved for 8, 10, and 12mm widths with up to 15° of lordotic correction, the system’s low-profile design is intended to facilitate insertion through constrained anatomy while minimizing tissue disruption and nerve retraction.
VersaLift features controlled in-situ expansion designed to maintain implant length throughout deployment while supporting restoration of anatomic disc height and indirect decompression of neural elements. Streamlined instrumentation is designed to help surgeons efficiently achieve alignment and procedural goals while maintaining a simplified workflow.
“VersaLift represents our continued focus on procedural innovation and minimally invasive spine surgery,” said Rich Mueller, President & CEO. “By combining a 6mm starting height with controlled in-situ expansion, VersaLift provides surgeons with a versatile expandable technology designed to address challenging anatomy while supporting procedural efficiency.”
For more information about Life Spine and its portfolio of spinal solutions, visit Life Spine.
About Life Spine, Inc.
Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com.
Contacts
Mr. Joe Fricano
Chief Financial Officer
jfricano@lifespine.com
847-884-6117
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Life Spine secured FDA 510(k) clearance for its VersaLift™ Expandable Interbody System, targeting the competitive TLIF and PLIF markets. This strategic move emphasizes minimally invasive solutions, offering a distinct 6mm starting height to address challenging anatomy and enhance procedural efficiency. The clearance positions Life Spine to potentially increase market share by providing a differentiated product that supports streamlined workflows and improved surgical access, appealing to surgeons seeking advanced, less invasive options.
- The system's low 6mm starting height provides a competitive advantage in minimally invasive TLIF/PLIF procedures.
- This clearance reinforces Life Spine's strategy of focusing on procedural innovation and efficiency in spinal disorder treatment.
PhD Lens: Clinical and outcomes impact
The VersaLift™ Expandable Interbody System, now FDA 510(k) cleared, is designed for TLIF and PLIF procedures. Its mechanism involves controlled in-situ expansion from a low 6mm starting height, aiming to restore anatomic disc height and provide indirect neural decompression. The system's design facilitates insertion through constrained anatomy, intending to minimize tissue disruption and nerve retraction, supporting minimally invasive surgical access.
- The device features controlled in-situ expansion and a 6mm starting height for minimally invasive access.
- It is intended to restore disc height, decompress neural elements, and minimize tissue disruption during TLIF/PLIF.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.